PubMed
Semax and its derivatives: neuroprotective peptides (review)
Ashmarin et al., 2018
Semax-family Analog
Nootropic research peptide in the Semax-family class; limited direct clinical evidence.
Overall check-ins
Trackers & reports
Overview
Nootropic research peptide in the Semax-family class; limited direct clinical evidence.
Community
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 98% · Mixed 2% · Unfavorable overall 0%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.6–1 mg · Most common: 0.2–0.4 mg
Reports span 0.2–2 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 92% said they felt similar to their last entry, 8% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 180 days · Based on 24 repeat reporters
Research
PubMed
Ashmarin et al., 2018
PubMed
Dmitrieva et al., 2013
Tools
More ways to learn about Adamax from observational PeptIQ data.
Related peptides
Help
This page summarizes 24 anonymized self-reports from PeptIQ users who track Adamax, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
2 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
This wiki does not assess safety or recommend use. Adamax is listed as Research Only. Consult a licensed clinician for personal medical decisions.
This wiki summarizes observational community reports and linked citations for Adamax. It does not assert therapeutic benefits. See the cited research list on this page and the educational profile for Adamax for study-level context — not medical advice.
Adamax is listed in PeptIQ as Research Only. Regulatory status varies by jurisdiction and can change. This wiki does not provide legal advice; check current FDA and local rules and talk with a licensed clinician or counsel for personal decisions.
Safety data quality for Adamax varies widely by compound and study design. PeptIQ does not establish a risk profile here. Review primary literature, product labeling where applicable, and clinician guidance. Community self-reports are not a substitute for clinical evidence.
This page links 2 indexed sources for Adamax. Evidence maturity differs by application — some peptides have large human programs, others are mostly preclinical. Treat citation counts as literature volume, not proof of efficacy.